Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20

RHYTHM PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$2.38 revenue$132,504,000

Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).
Net loss ($54.3M) or ($0.82)/share vs ($45.0M) or ($0.73)/share a year ago.
Cash and investments $416.1M at Sep 30, 2025, up from $320.6M at Dec 31, 2024.
Updated FY2025 non-GAAP operating expense guidance $295M-$315M excluding stock-based compensation.
PDUFA date Dec 20, 2025 for setmelanotide sNDA in acquired hypothalamic obesity; Phase 2 PWS data Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.